Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules

BACKGROUND: Poly(ADP-ribose) polymerase-1 (PARP) inhibitors (PARPi) exploit tumour-specific defects in homologous recombination DNA repair and continuous dosing is most efficacious. Early clinical trial data with rucaparib suggested that it caused sustained PARP inhibition. Here we investigate the m...

Descripción completa

Detalles Bibliográficos
Autores principales: Murray, J, Thomas, H, Berry, P, Kyle, S, Patterson, M, Jones, C, Los, G, Hostomsky, Z, Plummer, E R, Boddy, A V, Curtin, N J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3992512/
https://www.ncbi.nlm.nih.gov/pubmed/24556618
http://dx.doi.org/10.1038/bjc.2014.91

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3992512/
https://www.ncbi.nlm.nih.gov/pubmed/24556618
http://dx.doi.org/10.1038/bjc.2014.91

Ejemplares similares